Adar Biotech specializes in generation of monoclonal antibodies to weak and difficult antigens. Adar Biotech employs its novel products and protocols throughout the entire procedure. The numbers and properties of the resulting hybridoma clones are superior to those obtained by the traditional method.
We design immunogenic peptides with the aid of software added with our time-earned experience.
We immunize using novel adjuvant formulation - AdaTR and the optimized complementary protocol for maximizing response to weak and difficult antigens.
We select for hybridomas formation using our novel selection medium - the AdaGT that replaces common HAT selection medium. AdaGT does not contain aminopterin present in HAT medium. This results in minimizing toxicity to the sensitive emerging hybridomas colonies and improved hybridomas yields.
We screen earlier and faster for hybridomas with AdaBX screening technology. AdaBX technology enables earlier isolation and stabilization of promising hybridomas by cell cloning. Earlier cell cloning minimizes loss of positive hybridomas due to inherent genetic instability of these hybrid cells.